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Abstract
Objective:
A number of epidemiologic studies evaluated the prevalence of allergic rhinitis (AR), but few data are
available on its different clinical presentations. We addressed this survey to assess the features of AR in
children and adolescents.
Methods:
Thirty-five centers in Italy included 2623 pediatric patients with rhinitis, of whom 2319 suffered from AR,
while 304 had other kinds of rhinitis. For each patient a standardized questionnaire was filled in, including
ARIA classification, the duration of symptoms, the allergen identified as clinically relevant, the co-
morbidities, the kind of treatment, the response to treatment, the satisfaction with the treatment, and
the feasibility of allergen immunotherapy (AIT).
Results:
Of the 2319 patients, 597 (25.7%) had mild intermittent, 701 (30.2%) mild persistent, 174 (7.5%)
moderate–severe intermittent, and 773 (33.3%) moderate–severe persistent AR. The allergens most
relevant were grass pollen and dust mites. The most frequently used drugs were oral antihistamines
(83.1%) and topical corticosteroids (63.5%). The response to treatment was judged as excellent in
13.5%, good in 45.1%, fair in 30.8%, poor in 10%, and very bad in 0.6% of cases. The satisfaction
with treatment was judged as very satisfactory in 15.2%, satisfactory in 61.8%, unsatisfactory in 22.4%,
and very unsatisfactory in 0.5% of cases. AIT was considered indicated in 53.1% of patients with mild
intermittent, 79.2% of moderate–severe intermittent, 72.6% of mild persistent, and 82.7% of moderate–
severe persistent AR.
Conclusions:
The limitation of this study is that the population was not unselected and this prevents epidemiological
significance. These results offer confirmation of the adequacy of ARIA guidelines in classifying patients with
AR and of the association of severe phenotype with lack of success of drug treatment.
Introduction
Allergic rhinitis (AR) is a very common disease with a high and still increasing
world prevalence1. In Italy, the most recent data show a prevalence of AR of
18.9% in children and 35.1% in adolescents2. The burden of AR includes sub-
stantial social and economic costs related to such high prevalence, and to
impairment of patients’ daily activities, productivity, and quality of sleep3–5.
AR may have different clinical presentations according to the kind of symptoms
and their duration. The predominance of sneezing and nasal discharge or nasal
blockage inspired the definition of two subtypes of AR patients as ‘sneezers/
runners’ and ‘blockers’, respectively, and the period of occurrence of symptoms
defined the two forms of ‘seasonal’ or ‘perennial rhinitis’. A recent study found
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that sneezers/runners prevailed in seasonal rhinitis and
blockers prevailed in perennial rhinitis6. However,
the Allergic Rhinitis and its Impact on Asthma (ARIA)
document, endorsed by the World Health Organization,
introduced a new classification of AR based on duration
and severity of symptoms. Intermittent AR (IAR) was
defined by symptoms occurring for54 days/week or54
consecutive weeks, while persistent AR (PER) was defined
by symptoms occurring for44 days/week and44 consecu-
tive weeks. According to the kind of symptoms, a severity
scale of mild to moderate–severe (based on the AR impact
on both daily activities and quality of life) was suggested7.
The ARIA classification is currently widely used because
it was validated in general8 and also concerning the pedi-
atric population9.
We addressed this multicentric survey to assess the
prevalence of the different ARIA stages and the features
of the clinical presentations of AR in a large population of
children and adolescents.
Patients and methods
Thirty-five Pediatric Allergy Centers throughout Italy
included an overall number of 2623 patients presenting
with rhinitis. The diagnostic flow-chart suggested by
ARIA guidelines7,9 was used, based on a detailed clinical
history, to highlight the relationship between symptoms
and exposure to the various aeroallergens, on the results of
skin prick tests (SPT), and on the concordance between
history and SPT results. In patients with negative SPT,
nasal cytology was performed, as previously described10,
to assess the different types of non-allergic rhinitis.
Patients who also had a negative result in nasal cytology
were classified as having idiopathic rhinitis. For each
patient with AR the attending physician must fill in
a standardized questionnaire, which was previously vali-
dated by the Societa` Italiana di Allergologia e
Immunologia Pediatrica (SIAIP). The items on the
questionnaire were the ARIA classification of rhinitis,
the duration of symptoms, the results of SPT, the allergen
identified as clinically relevant, the co-morbidities, the
kind of treatment, the response to treatment, the satisfac-
tion with the treatment, and the feasibility of allergen
immunotherapy (AIT). Concerning the response to treat-
ment the outcome was assessed as excellent, good, fair,
poor and bad. Regarding satisfaction with treatment the
estimation was evaluated as very satisfied, satisfied, unsat-
isfied and very unsatisfied. Continuous parameters, such as
age and duration of symptoms, were reported as mean,
median, and standard deviation, while categorical param-
eters were reported as contingency tables. Data were stat-
istically analyzed by the chi-squared test for two data tables
and by log-linear models for more that two data tables.
A p value lower than 0.05 was considered significant.
Correlations were analyzed by linear regression.
Results
Out of the 2623 patients, 2319 (88.4%, 1388 children
[range: 5–13 yrs] and 931 adolescents [range: 14–17])
were diagnosed as suffering from AR, while 304 had
other kinds of rhinitis, the most common being infective
rhinitis (127 cases), non-allergic rhinitis with eosinophilia
(NARES, 59 cases), and idiopathic rhinitis (56 cases).
Of the 2319 patients with AR, 597 (25.7%) had mild
intermittent, 701 (30.2%) mild persistent, 174 (7.5%)
moderate–severe intermittent, and 773 (33.3%) moder-
ate–severe persistent AR; in 74 cases the data was missing.
The mean duration of AR was 3.1 2.4 years. Concerning
sensitization, Table 1 shows all the allergens eliciting
positive SPT and their clinical relevance as assessed by
patients’ history; 1092 patients were allergic to grass
pollen, 395 with intermittent and 701 with persistent
AR, 641 with mild and 456 with moderate–severe AR;
992 were allergic to dust mites, 280 with intermittent
and 670 with persistent AR, 587 with mild and 409 with
moderate–severe AR; 1018 patients had more than one
sensitization. Table 2 reports the identified co-morbidities.
Patients with no co-morbidities had a lower frequency of
mild AR, while patients with two or more co-morbidities
had a higher frequency of moderate–severe AR (p 0.01).
Table 1. Allergens eliciting a positive skin prick test (SPT) and their clinical
relevance.
Allergen Number of
positive SPT
% of total
(according to clinical relevance)
Grass pollen 1092 47.1
House dust mites 992 42.8
Parietaria pollen 352 15.2
Olive pollen 249 19.7
Betulaceae pollen 135 5.8
Cypress pollen 105 4.5
Alternaria spores 61 2.6
Animal epithelia 58 2.5
Compositae pollen 56 2.4
Ragweed pollen 44 1.9
Other pollens 18 0.8
Foods 4 0.2
Other allergens 171 7.4
Table 2. Reported co-morbidities in patients with AR.
Co-morbidity Number of cases (%)
Conjunctivitis 1200 (51.7)
Asthma 930 (40.1)
Sinusitis 240 (10.2)
Sleep disturbances 159 (6.9)
Adenoids/tonsils hypertrophy 153 (6.6)
Dermatitis 95 (4.1)
Cough 38 (1.6)
Nasal polyps 30 (1.3)
Urticaria 24 (1.0)
Oral allergy syndrome 10 (0.4)
Recurrent respiratory infections 9 (0.4)
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The most frequently used drugs were oral antihistamines
(1927 patients, 83.1%), and topical corticosteroids (1473
patients, 63.5%), followed by anti-leukotrienes (439,
18.9%), topical antihistamines (434, 18.7%), oral cortico-
steroids (119, 5.1%), nasal decongestant (91, 3.9%), chro-
mones (65, 2.8%), and others (477, 20.6%). Table 3
reports the treatments and their rate of use in the two
major causes of AR, grass pollen and dust mites. In 2208
questionnaires (95.2%) the response to treatment was
available: it was judged as excellent in 298 cases
(13.5%), good in 995 (45.1%), fair in 680 (30.8%), poor
in 221 (10%), and very bad in 14 (0.6%). In 2191 ques-
tionnaires (94.6%) the satisfaction with treatment was
available: the treatment was judged as very satisfactory
in 334 cases (15.2%), satisfactory in 1354 (61.8%), unsat-
isfactory in 491 (22.4%), and very unsatisfactory in 12
(0.5%). Figure 1 shows the correlation between response
to treatment and patients’ satisfaction, which was signifi-
cant (p50.01). The rate of dissatisfaction was 15.8% in
patients with mild AR and 32.4% in patients with moder-
ate–severe AR, this difference being highly significant
(p50.0001). The data on the suitability of AIT were
available in 2273 questionnaires: in 1618 cases (71.2%)
the treatment was considered by the attending physician
as indicated. This concerned 308 (53.1%) patients with
mild intermittent, 137 (79.2%) moderate–severe intermit-
tent, 502 (72.6%) mild persistent, and 626 (82.7%) mod-
erate–severe persistent AR. Considering the two major
causes of allergy, AIT was believed as suitable in 31.3%
of patients allergic to mites and in 28.6% of patients aller-
gic to grass pollen.
Discussion
The ARIA classification introduced reliable criteria for
identifying the clinical phenotype of patients with AR.
A recent study showed that the ARIA severity classifica-
tion in mild, moderate, and severe clearly discriminates
the impact of AR in all domains of quality of life and
categorized symptom score11. Of note, the adequacy of
the ARIA classification was also confirmed by the correl-
ation of the ARIA severity grade and nasal cytology,
which showed different cell counts according to different
severity; in particular, in moderate–severe AR signifi-
cantly increased counts of mast cells and lymphocyte or
plasma cells were found10,12. However, thus far the ARIA
staging has been used very rarely in epidemiologic stu-
dies13. In particular, one study on 1275 children in Spain
found that 7% of subjects had mild intermittent AR, 3.2%
had mild persistent AR, 52% had moderate–severe inter-
mittent, and 37.6% had moderate–severe persistent AR9.
The present study was aimed at investigating the features
of AR in a large population of children and adolescents.
Concerning the ARIA stage, 25.7% of patients had mild
intermittent, 30.2% had mild persistent, 7.5% had moder-
ate–severe intermittent, and 33.3% had moderate–severe
persistent AR. These data are different from those in the
Very Bad
Ve
ry
 u
ns
at
isf
ie
d
Un
sa
tis
fie
d
Ve
ry
 s
at
isf
ie
d
Sa
tis
fie
d
PA
TI
EN
T’
S 
SA
TI
SF
AC
TI
O
N
Poor
RESPONSE TO TREATMENT
Fair Good Excellent
r = 0.7885 p<0.01
Figure 1. Correlation between patients’ satisfaction and response to treatment. Linear regression analysis shows r¼ 0.7885 (p50.01).
Table 3. Treatments prescribed in grass-pollen-induced and mite-induced
allergic rhinitis (AR).
Treatment Grass-pollen-induced AR Mite-induced AR
Oral antihistamines 396 (86.8%) 364 (86.3%)
Topical corticosteroids 301 (66%) 309 (73.2%)
Antileukotrienes 96 (21.1%) 149 (35.3%)
Topical antihistamines 83 (18.2%) 55 (13%)
Bronchodilators 81 (17.8%) 86 (20.4%)
Oral corticosteroids 30 (6.6%) 36 (8.5%)
Nasal decongestants 18 (3.9%) 18 (4.3%)
Chromones 10 (2.2%) 12 (2.8%)
Others 115 (10.5%) 143 (11.8%)
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Spanish study cited above, only the rate of moderate–
severe persistent AR (36.7% vs. 33.3%) being comparable
in the two studies, while the rates of mild intermittent and
mild persistent AR were much higher in our study. It is
difficult to argue about such difference. The factor possibly
influencing the contrasting findings we may suppose is
that in the Spanish studies not only allergy centers but
also otorhinolaryngology centers (the number of which
was not reported) participated, and one may speculate
that children with mild AR are less likely to be referred
to the otorhinolaryngologist.
We analyzed a number of aspects for their possible asso-
ciation with AR phenotype, including the results of SPT,
the allergen identified as clinically relevant, the co-mor-
bidities, the kind of treatment, the response to treatment,
the satisfaction with treatment, and the feasibility of AIT,
that is the only available treatment acting on the causes of
allergy, being able to reduce the immunological and clin-
ical reactivity to the responsible allergen14. The results
highlighted interesting issues. Concerning the causative
allergens, grass pollen and house dust mites were confirmed
to be the twomajor actors in AR15,16, with no difference in
the distribution of mild and moderate–severe disease
and also of intermittent and persistent form in grass-
allergic or mite-allergic aspects. This further confirms
the suitability of the ARIA classification, because the
previous grouping in seasonal and perennial for grass
pollen- and mite-induced AR would not assess clinical
importance according to duration. Co-morbidities were
more common in patients with moderate–severe AR, the
commonest being conjunctivitis. The association of AR
with allergic conjunctivitis defines the picture of rhino-
conjunctivitis, which occurs very frequently17 and was pre-
sent in approximately 52% of the subjects we studied.
The other two most common co-morbidities were
asthma (40% of patients), and sinusitis (10% of
patients)7,18. Of note, an oral allergy syndrome was present
in only 0.4% of subjects. This seems to contrast with the
available data, that show much higher figures19, but the
kind of population we studied, including children and
adolescents, accounts for the difference, because sensitiza-
tion to foods cross-reacting with pollens or mites is delayed
and generally becomes clinically expressed in adults20.
Considering treatment, the most frequently used drugs
were oral antihistamines (83%) and topical corticosteroids
(63%). This is in accordance with the suggestions from the
ARIA guidelines, that reviewed the clinical efficacy of
such therapeutic agents by evidence from controlled
trials7,18. However, only a few studies explored patients’
satisfaction with prescribed treatments, which is a crucial
issue that may have a high clinical relevance by signifi-
cantly affecting treatment compliance. A large survey of
adult allergic patients has investigated patient and phys-
ician satisfaction with antihistamine treatment, showing
that second-generation antihistamines were considered by
both patients and physicians to be effective and well tol-
erated21. A similar study has been conducted in allergic
children: a better risk–benefit ratio was reported with the
second-generation antihistamine levocetirizine compared
with first-generation antihistamines, leading the authors
to conclude that levocetirizine seems to be a preferred and
appropriate future treatment choice for allergic children22.
However, the major limitation of these two studies is that
they were sponsored by the company producing levocetir-
izine. A recent survey on 301 adult patients with AR,
mostly treated with antihistamines and nasal corticoster-
oids, found that only 33.5% of them were satisfied with
treatments. Factors significantly associated with treatment
dissatisfaction were female gender, presence of co-morbid-
ities, and severity of rhinitis23. In the present study, the
response to treatment as assessed by the physician was
analyzed: it was judged as excellent in 13.5%, good in
45.1%, fair in 30.8%, poor in 10%, and very bad in 0.6%
of cases. Concerning satisfaction with treatment, the judg-
ment was very satisfactory in 15.2%, satisfactory in 61.8%,
unsatisfactory in 22.4%, and very unsatisfactory in 12
(0.5%) of cases. The data on response to treatment and
satisfaction with treatment was significantly correlated.
The judgment of poor and very bad concerning response
to treatment, and of unsatisfactory and very unsatisfactory
concerning satisfaction, warrant the highest attention
from physicians. In particular, dissatisfaction was signifi-
cantly more frequent in patients with moderate–severe AR
than in those with mild AR. A recent advance in the
improvement of therapeutic strategy in AR was achieved
by the understanding that patients with more severe AR
and resistance to drug treatment have, as demonstrated in
a controlled trial on 410 patients, a good response to
AIT24. Moreover, a recent post-hoc analysis of previously
published studies showed that the higher clinical efficacy
from immunotherapy is achieved in patients with more
severe AR25. The data on the suitability of AIT in our
survey showed that, with the exception of mild intermit-
tent AR, there were no significant differences in the rate of
indication for such treatment according to severity. This
attitude is likely to be influenced by the fact that the study
was performed in Pediatric Allergy Centers, where the
physicians have good knowledge of the characteristics of
AIT. In particular, the capacity to prevent asthma when
applied in children with rhinitis offers a clear advantage for
pediatricians26. Moreover, the indications in case of con-
comitant asthma27 and recent data suggesting the feasibil-
ity of AIT in patients with allergic polysensitization28 are
other issues favoring AIT. Also, its cost-effectiveness com-
pared with drug treatment, showed by a number of studies
andmainly due to themaintenance of clinical benefit once
AIT is discontinued29, further reinforce the role of this
treatment. The currently emerging data on the need for
optimally targeting patients with severe AR not controlled
by drugs needs to be acknowledged by pediatricians and
Current Medical Research & Opinion 2013
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specialists involved in diagnosis and treatment of AR to
provide these patients with an effective therapy.
Conclusions
This study confirms the adequacy of the ARIA guidelines
in identifying the clinical forms of AR, particularly when
the pediatric population is addressed. The phenotype of
severe AR insufficiently responding to drug treatment is
of special interest. Our findings show that in children and
adolescents with moderate–severe AR caused by inhalant
allergens both patients’ satisfaction and clinical success of
drug treatment, as judged by the physician, are scarce. This
deserves a search for more effective therapies for severe
AR, aimed at treating the cause of AR and not only its
symptoms, such as AIT.
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